Nano-x Imaging (NNOX) Soars 16.96% as AI Partnership Drives Investor Optimism

Nano-x Imaging (NNOX) surged 16.96% in pre-market trading on November 19, 2025, signaling renewed investor confidence ahead of the regular session. The sharp move followed a string of strategic developments and sustained analyst optimism about the stock’s long-term potential.

Analyst Jason Kolbert of D. Boral Capital reaffirmed a “Buy” rating for NNOX on November 18, maintaining an $8.00 price target. This marks the fourth consecutive “Buy” recommendation since May 2025, despite two downward adjustments to the price target. The latest guidance underscores confidence in the company’s core radiology services and AI-driven imaging solutions, which remain central to its revenue growth.

A key catalyst emerged with the announcement of a strategic reseller partnership with 3DR Labs, a major U.S. medical imaging services provider. Under the agreement, 3DR Labs will distribute Nanox.AI’s FDA-cleared AI solutions—HealthCCSng, HealthOST, and HealthFLD—to its network of over 1,800 hospitals and imaging centers. This partnership expands Nanox’s commercial reach and aligns with its focus on leveraging AI for early disease detection, a theme increasingly resonating with healthcare providers.

Backtesting scenarios suggest that positions held following analyst upgrades and strategic partnerships have historically outperformed in NNOX. A potential strategy could involve maintaining exposure ahead of key AI solution commercialization milestones, while monitoring technical levels for risk management. The $8.00 price target implies significant upside from current levels, assuming execution risks are mitigated.